OpSens Inc
Edit

OpSens Inc

https://opsens.com/
Last activity: 30.07.2024
Active
Categories: AerospaceDefenseEnergyTechIndustryITManufacturingMarketOilSensorsTechnology
OpSens focuses on the measure of FFR and dPR in interventional cardiology, offering an advanced optical-based pressure guidewire (OptoWire) that aims at improving the clinical outcome of patients with coronary artery disease. OpSens is also involved in industrial activities. The Company develops, manufactures and installs fibre optic sensing solutions for critical applications, such as the monitoring of oil wells and other industrial applications.
OpSens aims to become a key player in the FFR market with the OptoWire, a nitinol-based optical guidewire. The OptoWire provides intra-coronary blood pressure measurements with unique, patented technologies. Immune to the adverse effects related to blood contact, it allows easy and reliable connectivity that leads to reliable FFR measurements in extended conditions of usage. It is also designed to provide cardiologists with optimized performances to navigate coronary arteries and cross blockages with ease and safety. Based on industry sources, the FFR market represented more than US$300 M in sales in 2014. It is expected to reach US$1 B med-term.

OpSens Solutions, a leading manufacturer of fiber optic sensors, presents its latest advances with its White-Light Polarization Interferometry (WLPI) technology and its SemiConductor Band Gap (SCBG) technology.
With several new sensor models, OpSens Solutions provides high-accuracy, high-stability measurements, and high-resolution detection solutions to meet the needs of industries such as:
• Downhole fiber optic pressure and temperature sensor for Oil and Gas
• Temperature & pressure monitoring for Energy-related applications
• Precise instrumentation for Defense and Aerospace
• Customized OEM fiber optic sensor solutions
Our technology can measure temperature, pressure, linear displacement, constraint, force and load.
Our sensors perform in many harsh environments and at high temperatures. They are also insensitive to RF radiation, MRI, EMI, nuclear and microwave.
Mentions
15
Location: Canada, Quebec, Quebec City
Employees: 51-200
Total raised: $19.95M
Founded date: 2006

Investors 2

Funding Rounds 2

DateSeriesAmountInvestors
08.12.2016-$14.95M-
17.05.2016-$5MLumira Ven...

Mentions in press and media 15

DateTitleDescription
30.07.2024Haemonetics Announces CE Mark Certification for the SavvyWire® Pre-Shaped Pressure GuidewireBOSTON, July 30, 2024 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE), a global medical technology company focused on delivering innovative medical solutions to drive better patient outcomes, today announced CE Mark certification and th...
13.01.2022OpSens Announces FIRST Quarter fiscal 2022 Financial ResultsConference call on the results today at 11 a.m. ET QUEBEC, Jan. 13, 2022 /CNW Telbec/ - OpSens Inc. ("OpSens" or the "Company") (TSX: OPS) (OTCQX: OPSSF), a medical device cardiology-focused company delivering innovative...
23.11.2021OpSens Announces Fourth Quarter And Fiscal Year 2021 Financial ResultsConference call on the results today at 11 a.m. ET QUEBEC CITY, Nov. 23, 2021 /CNW Telbec/ - OpSens Inc. ("OpSens" or the "Company") (TSX: OPS) (OTCQX: OPSSF), a medical device cardiology-focused company delivering innov...
08.11.2021OPSENS' SAVVYWIRE™ Featured at the Transcatheter Cardiovascular Therapeutics 2021 Annual Meeting in OrlandoQUEBEC CITY, Nov. 8, 2021 /CNW/ - OpSens Inc. ("OpSens" or the "Company") (TSX:OPS) (OTCQX:OPSSF), a medical device company currently commercializing its proprietary sensing technology in the interventional cardiology ma...
13.10.2021OpSens Successfully Treats First Patients in Human Clinical Study for TAVR ProcedureQUEBEC, Quebec, October 13, 2021 – OpSens Inc. (TSX:OPS), a cardiology medical device company providing innovative product solutions based on its patented optical technology, is pleased to announce the commencement of the human clinical stu...
13.07.2021OpSens : Announces Third Quarter Fiscal 2021 Record Financial ResultsConference call on the results to be held today at 11 a.m. QUEBEC CITY, July 13, 2021 /CNW Telbec/ - OpSens Inc. ("OpSens" or the "Company") (TSX: OPS) (OTCQX: OPSSF), a medical device cardiology-focused company deliveri...
14.01.2020Opsens Receives FDA Approval for Optowire IIIQUEBEC CITY /CNW Telbec/ – Opsens Inc. (“Opsens” or the “Company”) (TSX: OPS) (OTCQX: OPSSF) today announced 510(k) clearance from the U.S. Food and Drug Administration (“FDA”) to market its OptoWire III, a coronary pressure guidewire for p...
08.11.2019First Clinical Use of the OptoWire III following Health Canada ApprovalQUEBEC CITY, QUEBEC – Opsens Inc. (“Opsens” or the “Company”) (TSX:OPS) (OTCQX:OPSSF) today announced the world’s first clinical use of the OptoWire III, following the recent Health Canada approval.
11.07.2019Opsens Releases Promising Q3 2019 FinancialsQUEBEC CITY, July 11, 2019 /CNW Telbec/ – Opsens Inc. (“Opsens” or the “Company”) (TSX: OPS) (OTCQX: OPSSF) today reported its results for the third quarter of 2019.
30.04.2019Opsens Signs Landmark Supplier Agreement – Expands Optical Sensing Technology Impact Within Cardiology SegmentQUEBEC CITY, April 30, 2019 /CNW Telbec/ – Opsens Inc. (“Opsens” or the “Company”) (TSX: OPS) (OTCQX: OPSSF) is pleased to announce it has entered into a supply agreement as part of its long-term collaboration with Abiomed, Inc. (“Abiomed”)...
Show more

Reviews 0

Sign up to leave a review

Sign up Log In